Earkart IPO Listing: Stock Lists at 0.37% Premium on BSE SME
Earkart IPO Listing: Shares Rise 5% After a Flat Start, Hit Upper Circuit
Mumbai, October 3 – Healthtech platform Earkart Limited made its debut on the stock markets today with a subdued opening, listing at ₹135.50 on the BSE SME platform — a marginal premium of 0.37% over its IPO price of ₹135. However, investor sentiment improved soon after, as the stock witnessed steady buying interest and gained 5% to hit the upper circuit limit of ₹142.25, reflecting increasing confidence in the company’s long-term prospects.
Though the initial listing was flat, the subsequent surge underscored market optimism for Earkart’s niche position in the healthcare segment, particularly in hearing aids and disability support devices — a market that has seen increasing demand amid growing awareness and accessibility.
About Earkart Limited
Earkart Limited is a specialized healthtech company focused on the diagnosis, distribution, and sales of hearing aids and other assistive devices. The company offers a wide range of advanced hearing solutions, including:
- Receiver-in-Canal (RIC)
- Invisible-in-Canal (IIC)
- Behind-the-Ear (BTE)
- In-the-Ear (ITE)
- In-the-Canal (ITC)
- Completely-in-Canal (CIC)
In addition to hearing aids, Earkart also provides products that cater to the broader disabled community, such as adjustable foldable walkers, multi-sensory integrated educational development (MSIED) tools, and teaching learning materials (TLM). These products are distributed via a network of clinics and partners, both within India and internationally.
By positioning itself at the intersection of technology, healthcare, and accessibility, Earkart aims to empower individuals with hearing loss and other physical disabilities by enhancing their quality of life.
IPO Details and Market Response
Earkart’s Initial Public Offering (IPO) was open for subscription between September 25 and 29, 2025. The company aimed to raise a total of ₹49.26 crore, comprising:
- A fresh issue of 33 lakh shares amounting to ₹44.75 crore
- An Offer for Sale (OFS) of 3 lakh shares, aggregating to ₹4.51 crore
Despite a challenging market environment and mixed investor sentiment in recent SME listings, the Earkart IPO managed to receive moderate interest, being subscribed 1.28 times overall. Here’s a breakdown of the subscription:
- Non-Institutional Investors (NIIs): Subscribed 1.63 times
- Retail Individual Investors (RIIs): Subscribed only 0.35 times
The relatively low retail participation suggests a cautious approach among small investors, possibly due to recent volatility in SME stocks or limited awareness about the company’s business model. However, the higher subscription by non-institutional investors reflects interest from HNIs and seasoned investors, who often take a long-term view and recognize the potential of niche healthcare plays.
Financial Performance and Growth Outlook
Earkart has demonstrated solid financial growth in recent years, showcasing the strength of its business model and increasing market penetration. For the fiscal year ending March 2025 (FY25), the company reported:
- Revenue: ₹43.19 crore, up 35% from ₹31.97 crore in FY24
- Net Profit: ₹6.88 crore, up 125% from ₹3.06 crore in FY24
- Total Borrowings: ₹4.96 crore (FY25)
This impressive growth in profitability — more than doubling in just a year — signals improving operational efficiency and cost management, as well as rising demand for the company’s products. The increase in revenue also reflects Earkart’s expanding market footprint, both in India and abroad.
Despite being in a capital-intensive sector, the company has managed to keep its borrowings relatively low, suggesting prudent financial management. The IPO proceeds are expected to be deployed toward working capital requirements, expansion of distribution networks, R&D, and technological upgrades — all of which could further strengthen its competitive position.
Industry Landscape and Competitive Edge
The global hearing aids market is expected to grow significantly over the next decade, driven by an aging population, increasing prevalence of hearing loss, and rising adoption of digital hearing solutions. In India alone, millions of people suffer from hearing impairments, but the penetration of hearing aids remains relatively low compared to global averages.
Earkart is well-positioned to capitalize on this untapped market due to its:
- Diverse product portfolio
- Affordable pricing
- Strong partner network
- In-house R&D capabilities
Additionally, its foray into educational aids and products for the physically disabled opens up multiple revenue streams, reducing over-dependence on a single product category. This diversification could prove crucial in sustaining growth and maintaining investor interest over the long term.
What’s Next for Earkart?
Post-listing, all eyes will be on Earkart’s execution strategy. Investors will be looking for:
- Consistent quarterly performance
- Expansion of retail and clinical presence
- Innovation in assistive tech
- Successful deployment of IPO funds
Given the relatively small size of the IPO and the modest free float, the stock may continue to witness low liquidity and high volatility, which is common in BSE SME stocks. However, for long-term investors who believe in the company’s mission and market potential, Earkart may offer a compelling growth story in the emerging healthtech space.
Final Thoughts
Earkart Limited’s listing may have started on a quiet note, but the sharp 5% rise and upper circuit hit on Day 1 send a strong signal of investor confidence in the company’s growth potential. While the IPO subscription numbers were not overwhelmingly high, the strong financials, niche market positioning, and expanding demand for healthcare assistive devices present a promising outlook for the company.
As the company embarks on its next phase as a listed entity, Earkart’s ability to deliver on its promises, maintain profitability, and scale operations will be key to sustaining market interest and unlocking shareholder value in the long run.
